Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
10 juil. 2024 08h05 HE
|
Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
10 juil. 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
ImCheck Appoints Stephan Braun as Chief Medical Officer
09 juil. 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Appoints Stephan Braun as Chief Medical Officer Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
08 juil. 2024 20h00 HE
|
Io Therapeutics, Inc.
Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
08 juil. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Memo Therapeutics AG appoints Paul Carter as Chairperson
08 juil. 2024 07h00 HE
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public...
Memo Therapeutics AG appoints Paul Carter as Chairperson
08 juil. 2024 02h00 HE
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
03 juil. 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s...
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
02 juil. 2024 08h00 HE
|
Bionano Laboratories
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect...
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
01 juil. 2024 08h00 HE
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatm